Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,248.09
(
-1.03%
)
News Focus
News Focus
Post# of 5032596
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Edward

Send PM Follow Ignore
Followers 40
Posts 7324
Boards Moderated 3
Alias Born 05/06/2014

Edward

Re: None

Thursday, 12/01/2022 8:42:35 AM

Thursday, December 01, 2022 8:42:35 AM

Post# of 5032596
CTXR

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma


https://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Announces-U.S.-Food-and-Drug-Administration-Acceptance-of-Biologics-License-Application-of-Denileukin-Diftitox-for-the-Treatment-of-Patients-with-Persistent-or-Recurrent-Cutaneous-T-Cell-Lymphoma/default.aspx
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today